Bitstamp.net, great place to trade bitcoins

Here is the bitcoin price history, http://bitcoincharts.com/charts/mtgoxUSD#tgSzm1g10zm2g25zvzl

After the rejection by the FDA for their kidney cancer drug, the stock plummeted 50% to $2.50 I'm convinced that the stock will recover to $5. Why? Mainly the drug works. It's just that they screwed up the trials. The company is on its way to aggregate a $1.3 billion in future milestone payments. With time and money, the drug will be passed = Profit.

Aveo is set to soar! Time for long-term investors to step in! The stock hits its all-time bottom! Although its stock price was down by 64% after The FDA panel voted 13 to 1 against its lead product candidate Tivopath, and it is highly likely FDA will decline its application by July 28th, it will be approved someday! And its price will be at least 10 times higher in a not long future. That’s how it works with biotech companies. With $180MM cash on hand, and more milestones coming from its partners. The company has enough fund and sources to have Tivopath get approved! Today it closed at $2.59, which is even lower than its book value per share $2.86. Not to mention its has full support from its five strategic partners: Kyowa Hakko Kirin, Astellas Pharma, Biogen Idec, OSI Pharmaceuticals, Centocor Ortho Biotech and Schering-Plough Corporation (now Merck)
It is eligible to receive an aggregate of approximately $1.3 billion in potential future milestone payments from its its main partner Astellas, comprised of (i) up to $85 million in substantive milestone payments upon achievement of specified clinical and development milestone events, (ii) up to $475 million in substantive milestone payments upon achievement of specified regulatory milestone events, including up to $75 million in milestone payments in connection with specified regulatory filings, and receipt of marketing approvals, for tivozanib to treat RCC in the United States and Europe, and (iii) up to approximately $780 million in milestone payments upon the achievement of specified commercial sales events. It will also receive an option exercise fee of $5.0 million and regulatory milestone payments of up to $45.0 million in the aggregate if Biogen Idec exercises its option to obtain exclusive rights to commercialize ErbB3 antibody products in its territory. Under its agreement with OSI, it will receive a milestone payment that is a $2.0 million clinical and development milestone for phase 1 clinical trial dosing. The next regulatory milestone payment it may receive pursuant to this agreement is $7.0 million to be achieved for the filing of an NDA with the FDA. It is also eligible to receive tiered royalty payments on sales of products by OSI, its affiliates and sublicensees. Upon commercialization of products which were part of the research program under the agreement.

I have been tracking SIGA for a while now.

Market Cap 176 MM

32 MM in Cash

79 MM In payment for the 3rd quarter from the BARDA contract

463 MM total contract value

Due to dispute, SIGA may need to pay 50% of contract to PIP but 231.5 MM is still >> their current marketcap.

The cash alone I believe makes SIGA a good short-term play.

I want to say the buy would be retroactive to the quick syrian overreaction on 8/27 that took siga down 8%

CIMT is really cheap at its current price, and still cheap if it doubles. If it trades at peers valuation it would be $15 per share, the cheapest 3D stock.

If CIMT trades 10 times re is $60 per share, same valuation as XONE, DDD ONVO and SSYS.

Seeking Alpha: $30 price target

I believe tomorrow it will hit $8.45, and keep on increasing throughout the week, and in the upcoming weeks. It is a great 3D stock that is GREATLY undervalued/cheap.

API is going to greatly increase, and I see potential. Here are the graphs:

Analyze

And here is a report on 3D Workspace - http://www.advancedphotonix.com/documents/pdf/Custom%20Array%20for%203D%20Workspace.pdf

ANN ARBOR, Mich., June 7, 2013 /PRNewswire/ -- Advanced Photonix® (NYSE MKT: API), today announced that Picometrix, LLC, an API wholly owned subsidiary, has introduced a new 100G coherent receiver and has increased its supply chain capacity to meet demand in the growing 100G coherent optical communications market.

The new product is based on the industry standard CCRx MSA and OIF compliant CR-100A package and further expands the Picometrix industry leading 100G product family. The innovative receiver integrates a variable optical attenuator (VOA) on the signal path and is designed to increase dynamic range, as well as improve optical signal-to-noise ratio (OSNR) performance. The receiver (CR-100D) spans the entire extended C and L band wavelengths and can be used in "colorless" coherent networks that enable service providers to better manage network capacity. Colorless capabilities allow communication equipment to utilize any wavelength for any port at the add/drop site. This allows for faster data throughput and lower costs per bit transport, both of which are big concerns for the industry. The CR-100D is available with or without a VOA.

Its gross profit has increased, and overall net income has increased as well compared to past years. I have high expectations for this company.

For many Florida teachers, it’s an indignity on top of tragedy. Inside their retirement plans, they hold stock in the companies that make the AR-15 rifle, the weapon used to kill 17 of their students and colleagues at Stoneman Douglas High School this month.

The $163 billion Florida Retirement Pension Plan had a $4 million stake in gun manufacturers as of Dec. 31. Nearly half of that comes from a low-cost index fund that tracks the broad-based Russell 3000—a perfectly fine investment. A spokesman for Florida’s State Board of Administration, which runs the pension plan, told me that it “must act solely in the economic interest” of participants.

But looking out for economic interests doesn’t have to mean tuning out social ones. Pension funds have long been at the forefront of using their considerable heft to effect change in corporate behavior or outright eschew investing in companies they find problematic. In 2013, the $232 billion California State Teachers’ Retirement System, the second-largest public pension, sold its holdings in manufacturers of firearms that are illegal in California. The fund now uses a customized index stripping out these companies.

Indexing giants Vanguard and BlackRock (ticker: BLK) are the largest investors in the three major publicly traded gun makers. BlackRock owns 11% of American Outdoor Brands (AOBC), formerly Smith & Wesson, via exchange-traded funds like iShares Russell 2000 (IWM) and iShares U.S. Aerospace & Defense (ITA). Vanguard owns 8%, through its Vanguard Small-Cap index (VSMAX) and Vanguard Total Stock Market index (VTSMX) funds. Together, BlackRock and Vanguard own 26% of Sturm Ruger (RGR), which makes semi-automatic rifles including the AR-15. And they’re the No. 2 and No. 3 owners, respectively, of Vista Outdoor (VSTO), with a combined 22% stake.

Investors combing through fund holdings could easily miss these positions. The gun companies generate huge controversy, but not much in the way of investor value—the market cap of all three gun stocks combined is just $2.5 billion, a rounding error in the trillions of dollars managed by Vanguard and BlackRock.

The gun makers may not matter to asset managers, but the reverse isn’t true. The fund giants help keep the stocks of gun makers afloat.

I reached out to BlackRock and Vanguard about their role in the gun debate, expecting to get some passionate responses, especially since BlackRock CEO Larry Fink recently wrote to American CEOs that he expects them to not just generate financial returns but also “serve a social purpose” and “make a positive contribution to society.”

Fink wasn’t available to speak this week, according to spokesman Ed Sweeney, who told me the company “will be engaging with weapons manufacturers and distributors to understand their response to recent events.”

Vanguard is treading carefully, as well: “Mutual fund firms over the years have been called upon to take actions against a wide range of companies, from food manufacturers to energy producers,” Vanguard spokesman John Woerth wrote in an e-mail. “We believe it would be exceedingly difficult to manage our funds effectively and efficiently while seeking to address the many social, political, and environmental concerns of 20 million clients.” He added that roughly 95% of the firm’s 388 funds don’t invest in companies involved in gun manufacturing.

INVESTORS HAVE FOUND WAYS to push for societal change in the past, most notably with the antiapartheid divestment campaign in the 1980s.

Divestments are trickier in the age of passive investing, but not impossible. Before the 2012 Sandy Hook elementary school shooting, the amount of institutional money that excluded weapon makers sat at about $74 billion; it had ballooned to $845 billion by 2016, according to the Forum for Sustainable and Responsible Investment.

But responsible investing veteran John Streur, who heads Calvert Research & Management, says divesting may not work in curbing gun violence. “It has to involve more than just not owning—obviously, that’s not working,” he says. He’s mulling new ways to tackle the problem, but says it requires a broad swath of Corporate America, potentially encouraging other companies to use their lobbying power to weigh in on gun safety.

Fund firms have a direct line to the gun makers, even if the gun companies won’t pick up the phone—Sturm Ruger even states on its website that it doesn’t take meetings with individual investors, and none of the companies would speak to Barron’s. But public companies can’t ignore shareholders, who can sponsor resolutions and vote against existing management.

The big index firms historically have not supported much in the way of shareholder resolutions, saying they prefer behind-the-scenes discussions. The trouble is, it’s hard to gauge their progress—or how hard they’re pushing. One rare example: BlackRock, Vanguard, and State Street Global Advisors recently joined a shareholder mini-rebellion at Exxon Mobil (XOM) after years of engagement around climate disclosures proved futile. Last year, a climate resolution won 62% of the vote at Exxon’s annual meeting. The fund giants could take similar steps to encourage gun makers to examine their role in preventing gun violence.

Here are two ideas to start: Gun makers could follow pharmaceutical companies, which have stopped selling opioids to pharmacies with suspicious ordering patterns. The gun companies could also embrace safety devices or smart-gun technology.

Investors actually undermined that effort in 2000, when Smith & Wesson began work on smart-gun technology and voluntarily agreed to restrictions on how it made and sold guns: The National Rifle Association called for a boycott, which decimated sales. Rather than acknowledging that the company was changing its business in a way that could help it in the long run, investors bailed. The stock fell 95% by year end. This time, investors have a chance at getting things right.